Pharmaceutical company AstraZeneca committed to investing $50 billion in the United States by 2030. The company will fund a new manufacturing facility in Virginia focused on studying chronic diseases.
“The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company’s innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products,” the company explained. “The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.”
The forthcoming facility will be the company’s largest single manufacturing investment and will draw upon AI, automation, and data analytics for production optimization.
Pascal Soriot, CEO of AstraZeneca, said, “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”
Commerce Secretary Howard Lutnick called the investment a “win for American manufacturing.” He noted that the development “shows our tariff strategy at work” and “will bring high-paying jobs to Virginia, Indiana, Texas, and across the country while hardening our supply chains. Reshoring pharma production is one of our top priorities.”
President Trump recently threatened to impose tariffs as high as 200% on imported pharmaceuticals.
